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Background: Cyclophilin A (CyPA), a receptor of the immunosuppressive drug
cyclosporin A, catalyzes the cis-trans isomerization of peptidyl–prolyl bonds and
is required for the infectious activity of human immunodeficiency virus type 1
(HIV-1). The crystal structure of CyPA complexed with a fragment of the HIV-1
gag protein should provide insights into the nature of CyPA–gag interactions
and may suggest a role for CyPA in HIV-1 infectious activity. 
Results: The crystal structure of CyPA complexed with a 25 amino acid peptide
of HIV-1 gag capsid protein (25-mer) was determined and refined to an R factor
of 0.195 at 1.8 Å resolution. The sequence Ala88-Gly89-Pro90-Ile91 of the gag
fragment is the major portion to bind to the active site of CyPA.  Two residues of
the 25-mer (Pro90-Ile91) bind to CyPA in a similar manner to two residues (Pro-
Phe) of the CyPA substrate, succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (AAPF).
However, the N-terminus of the 25-mer (Ala88-Gly89) exhibits a different
hydrogen-bonding pattern and molecular conformation than AAPF. The
peptidyl–prolyl bond between Gly89 and Pro90 of the 25-mer has a trans
conformation, in contrast to the cis conformation observed in other known
CyPA–peptide complexes. The residue preceding proline, Gly89, has an
unfavorable backbone conformation usually only adopted by glycine.
Conclusions: The unfavorable backbone conformation of Gly89 of the gag
25-mer fragment suggests that binding between HIV-1 gag protein and CyPA
requires a special sequence, Gly-Pro. Thus, in HIV-1 infectivity, CyPA is likely to
function as a chaperone, rather than as a cis-trans isomerase. However, the
observation of similarities between the C termini of the 25-mer and the substrate
AAPF means that the involvement of the cis-trans isomerase activity of CyPA
cannot be completely ruled out.
Introduction
Cyclophilin (CyP) binds the immunosuppressive drug
cyclosporin A (CsA) [1], and is also an enzyme with pep-
tidyl–prolyl cis-trans isomerase activity [2,3]. The CyP–
CsA complex binds to calcineurin, a serine/threonine
phosphatase and a Ca2+-dependent calmodulin-binding
protein [4–6].
The isomerization of peptidyl–prolyl amide bonds forms a
slow step in protein folding, and CyP was reported to
accelerate protein or oligopeptide folding [7–16]. The
cyclophilin homolog NinaA was shown to form a stable
complex in vivo with rhodopsin, and to function as a chap-
erone [17]. In addition, a chaperone complex, required for
the folding of steroid receptors, was formed between
cyclophilin-40, heat shock proteins (hsp70 and hsp90), and
the protein p23 [18].
Cyclophilin A (CyPA) has been reported to bind human
immunodeficiency virus type 1 (HIV-1) gag protein [19],
and is required for the infectious activity of HIV-1 virions
[20–22]. HIV gag is a polyprotein and is cleaved by pro-
teases into several functional proteins: matrix (MA), capsid
(CA), nucleocapsid (NC), and small peptides [23,24].
HIV-1 CA protein (also known as gag p24 or p24) is essen-
tial for the assembly and infectivity of HIV virions [23].
Binding of CyPA to the HIV-1 gag protein is mediated by
the central region of CA [25–27]. Recently, the NMR
structure of the N-terminal domain of CA (residues 1–151)
[28] and the partial crystal structure of CA complexed with
an Fab fragment [29] have been determined.
Three-dimensional structures have been reported for the
unligated recombinant human T cell CyPA [30,31] and
CyPA complexed with various proline-containing peptides:
N-acetyl-Ala-Ala-Pro-Ala-amido-methylcoumarin (AAPA)
[32,33], Ala-Pro [34], Ser-Pro, His-Pro, Gly-Pro [35],
succinyl-Ala-Pro-Ala-p-nitroanilide (APA) [36], and suc-
cinyl-Ala-Ala-Pro-Phe-p-nitroanilide (AAPF) [37]. These
structures have provided insight into the mechanism of 
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the peptidyl–prolyl cis-trans isomerization. We report here
the structure of CyPA complexed with a 25 amino acid
peptide (25-mer) from the HIV-1 gag CA protein (residues
81–105 of gag). This structure indicates the probable
nature of the interactions of CyPA with the HIV-1 gag
protein, and suggests a role for CyPA in HIV-1 infectious
activity.
Results and discussion 
Binding of the 25-mer does not change the CyPA structure
The structure of CyPA complexed with the 25-mer of gag
CA is an eight-stranded b barrel (Fig. 1), similar to the
structures of unligated CyPA [30,31] and its complexes
with proline-containing peptides [32–37]. The superposi-
tion of the CyPA–25-mer structure onto unligated CyPA,
or its complex with the tetrapeptide AAPF, revealed an
average positional shift of 0.27Å for the Ca atoms. This
observation indicates that binding of the 25-mer does 
not induce substantial changes on the structure of CyPA.
However, in unligated CyPA a loop of six residues
(Ala101–Asn106) moved significantly to accommodate the
binding of the 25-mer fragment, as shown by its Ca posi-
tional shift of 0.86Å; this shift is more than three times the
overall average Ca shift of 0.27Å. A similar movement was
also observed in the structure of CyPA–AAPF; the average
Ca shift is 0.97Å for Gly104–Pro105 and 0.58Å for
Ala101–Asn106, relative to unligated CyPA.
The electron density was excellent for most residues of
CyPA. The N-terminal methionine, which was not visible
in the crystal structures of the unligated or peptide-com-
plexed CyPA [31,34,35,37] was well ordered in the CyPA–
25-mer structure. The average B factor was 30.6Å2 for the
N-terminal Met1, and is comparable with the overall
average B factor of 24.8Å2 for all atoms of CyPA.
The 25-mer gag fragment was partially observable:
residues Val86–Arg97 (gag numbering) were well ordered
(Fig. 2) while the N terminus (Asp81–Pro85) and the
C terminus (Glu98–Ala105) were not traceable because of
lack of electron density. However, when we looked care-
fully at the crystallographic lattice packing, there was
some extra space available that might be occupied by dis-
ordered regions of the ligand. The 25-mer has been
reported to bind CyPA in solution by circular dichroism
(CD) spectroscopy and has further been characterized by
two-dimensional exchange 1H-NMR spectroscopy as a
substrate for CyPA (U Reimer et al., unpublished data).
Thus, it seems likely that the 25-mer binds to CyPA in the
similar buffer system used for crystallization, and that the
complete 25-mer is present in the crystal with disordered
N and C termini. We cannot exclude the possibility of
some unknown cleavage. The average B factor was 36.4Å2
for all the atoms of Val86 to Arg97 of the 25-mer. This
B factor is slightly higher than the average B factor of
24.8Å2 for CyPA. However, the average B factor for
Ala88–Gly94 of the 25-mer, which forms the central
portion for binding, was 29.1Å2 implying ordered binding
in a 1:1 ratio of CyPA:25-mer. The high B factor for the N
and C termini may reflect their thermal mobility and lack
140 Structure 1997, Vol 5 No 1
Figure 1
Crystal structure of CyPA complexed with a fragment of HIV-1 gag
protein. (a) Molecular surface charge distribution: the positively
charged regions are shown in blue and negatively charged regions are
in red. The 25-mer of gag capsid protein is represented in green and
its sidechains are in yellow. (Figure drawn using GRASP [49].) 
(b) Ribbon representation: helices are shown in red, b strands in
orange and loops in blue. Residues of the 25-mer are shown as a
yellow stick model. (Figure plotted using the program MOLSCRIPT
[50] and Raster3D [51].)
of interaction with CyPA. The peptide conformational
angles of f and ψ for all residues of CyPA, and for the
traced 25-mer fragment with the exception of glycine,
were located within the energy-allowed regions of a
Ramachandran plot [38].
Interactions between the 25-mer and CyPA
The 25-mer fragment of HIV-1 gag was bound at the
active site on the molecular surface of CyPA. Fourteen
CyPA residues (Arg55, Ile57, Phe60, Met61, Gln63,
Asn71, Gly72, Thr73, Ala101, Asn102, Gln111, Phe113,
Leu122 and His126) were involved in interactions with
nine 25-mer residues (Val86, His87, Ala88, Gly89, Pro90,
Ile91, Ala92, Pro93 and Nle96) (Table 1). The 25-mer has
the same N- to C-terminal peptide chain direction as the
tetrapeptide AAPF, but is in the opposite direction to that
of CsA [39–42]. The sidechain of Pro90 of the 25-mer
occupies the hydrophobic pocket of CyPA, which is made
up of residues of Phe60, Met61, Phe113, Leu122 and
His126. There are eight hydrogen bonds between the
25-mer and CyPA (Table 1; Fig. 3). Six of these hydrogen
bonds involve the backbone of Ala88–Ile91 of the 25-mer,
while two are formed between the sidechains of His87 and
Gln95 of the 25-mer and the Asn71 carbonyl oxygen and
the Arg55 sidechain of CyPA. In addition, six water mol-
ecules form hydrogen bonds with the 25-mer fragment
(Table 1). These findings are consistent with the results
from a yeast two-hydrid system in conjunction with a
binding assay [26], with the NMR structure of the N-ter-
minal domain of unbound CA [28], and with the crystal
structure of the Fab–CA complex [29].
There are four proline residues in the 25-mer fragment
(Pro85, Pro90, Pro93 and Pro99). While Pro85 and Pro99
were not visible, Pro90 and Pro93 were seen to have a
trans peptide conformation. The trans peptide conforma-
tion of Pro90 in the crystal structure is comparable with
the conformation of the unbound N-terminal domain of
CA [28] and the 25-mer (U Reimer et al., unpublished
data) observed in NMR structures, but is in contrast to the
cis conformation of proline-containing peptides in complex
with CyPA [32,37,43]. On the other hand, Gly89 of the 25-
mer had unusual backbone conformational angles of
f=133° and ψ=160°; this unfavorable backbone confor-
mation can only be adopted by glycine.
The 12 amino acids of the 25-mer that could be traced
comprised an extended backbone of Val86–Ala92 and 
a 310 helix of Pro93–Arg97 (Table 2). The extended con-
formation of Val86–Ala92 is similar to the NMR solution
structure of the N-terminal domain of unbound CA.
However, Ala92–Gln95 adopted a type II b turn in the
solution structure [28], but a type III b turn in our crystal
structure (Table 2). Moreover, the 310 helix of Pro93–
Arg97 observed in the crystal structure was not reported
in the solution structure [28]. These differences could
either reflect a change in the conformation of the 25-mer
from free solution to the bound state or represent a false
difference resulting from the limited resolution of the
methods.
The strand from Ala88–Ile91 of the 25-mer forms the
main interactions with CyPA, including six hydrogen
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Figure 2
Stereo plot of electron density of the 25-mer
fragment. Residues of Asp81–Pro85 and
Glu98–Ala105 were not visible in the
electron-density maps. The residues shown in
thick lines are: Val86-His87-Ala88-Gly89-
Pro90-Ile91-Ala92-Pro93-Gly94-Gln95-
Nle96-Arg97. The electron density shown as
thin lines is calculated from the refined
structure in which the 25-mer fragment was
omitted. The (2Fo–Fc) map is contoured at
1.0s. The peptide bonds of all the proline
residues in the bound 25-mer fragment have a
trans conformation. C
1
C
bonds and numerous hydrophobic contacts. A superposi-
tion between CyPA–25-mer and CyPA–AAPF, using only
the CyPA structure as a probe, revealed that Ala88–Ile91
of the 25-mer corresponds to the tetrapeptide AAPF
(Fig. 4). Pro90–Ile91 of the 25-mer and Pro3–Phe4 of
AAPF occupy the same site, with small positional shifts 
of 0.18 and 0.28Å for their Ca atoms and 0.45Å for the
proline sidechain. These residues also share the same
pattern of hydrogen bonding. For example, their carbonyl
oxygens both form hydrogen bonds with the sidechains of
Arg55 and Trp121 (Table 1; [37]). However, Ala88–Gly89
of the 25-mer showed some dramatic differences from
Ala1–Ala2 of AAPF: Ala88–Gly89 showed large Ca posi-
tional shifts of 2.4 and 2.7 Å (about ten times the average
value of 0.27Å for all Ca atoms of the structures); differ-
ences were seen in the interactions with CyPA; and the
backbone conformation of the two peptides was not the
same (Fig. 4; Table 2). 
Is cis-trans isomerization involved in HIV-1 infectivity?
The unusual bound conformation of the 25-mer in the
crystal structure suggests that the peptidyl–prolyl cis-trans
isomerase activity of CyPA is unlikely to be involved in
HIV-1 activity. Firstly, the residue preceding proline,
Gly89, has a backbone conformation of f=133° and
ψ=160°, located in the energy-disallowed region of the
Ramachandran plot [38]. This unfavorable backbone con-
formation is usually adopted only by glycine because of
stereochemical restraints. Therefore, the binding of the
HIV-1 gag protein to CyPA, which requires a special
sequence of Gly–Pro, does not have the general character
of cis-trans isomerization that presumably accepts a
sequence with any types of amino acids preceding proline.
Secondly, the binding of Pro90, but not Pro85, Pro93 or
Pro99 of the 25-mer, implies that the interactions between
gag CA and CyPA are sequence specific. If cis-trans iso-
merization of a peptidyl–prolyl bond played a key role in
HIV-1 gag protein folding, it might be predicted that the
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Table 1
Interactions between the 25-mer and CyPA.
25-mer CyPA Distance (Å)
Hydrogen bonds
His87:ND1 Asn71:O 2.85
His87:NE2 Wat76:O 2.82
Ala88:N Gly72:O 2.89
Ala88:O Gln63:NE2 3.18
Ala88:O Wat50:O 2.64
Gly89:N Asn102:O 2.82
Gly89:O Wat56:O 2.96
Pro90:O Arg55:NH1 2.70
Pro90:O Arg55:NH2 2.77
Ile91:O Trp121:NE1 3.09
Ile91:N Wat41:O 3.21
Gly94:O Wat59:O 3.03
Gln95:OE1 Arg55:NH1 2.88
Arg97:O Wat59:O 2.96
Hydrophobic or 
polar interactions*
Val86 Thr73
His87 Asn71, Gly72, Thr73
Ala88 Gln63, Gly72, Asn102, Gln111
Gly89 Arg55, Gln63, Ala101, Asn102
Pro90 Arg55, Phe60, Met61, Gln63,
Phe113, Leu122, His126
Ile91 Phe60, Trp121
Ala92 Ile57, Phe60
Pro93 Phe60, Trp121
Nle96 Trp121
*A distance of 3.2–4.0Å is defined as a hydrophobic or polar interaction.
Figure 3
Stereo plot of the active site of CyPA
complexed with the 25-mer fragment. Thin
lines represent the backbone traces of
Ser52–Phe65 and Gly97–His126 and some
sidechains of the active-site residues of
CyPA; thick lines represent the residues of
the gag 25-mer fragment. Water molecules
(Wat) are marked as small triangles and
dotted lines represent hydrogen bonds
between the 25-mer, water molecules, and
protein atoms. (The detailed interactions are
listed in Table 1.) 
Trp121
Arg55
Gln63
Asn71
Gly72
Asn102
Wat76
Wat50
Wat56
Wat41
Wat59
four prolines of the 25-mer would bind equally to the
active site of CyPA. Guidance for this prediction is pro-
vided by the crystal structure, which reveals that interac-
tions between the 25-mer and CyPA mainly involve the
CyPA backbone atoms (Ala88–Ile91) and the sidechain of
Pro90 of the 25-mer (Table 2). 
Several lines of evidence from genetic and biochemical
studies support the above argument. Site-directed muta-
genesis showed that the mutation of Pro90 to alanine abol-
ished the binding of full length gag to CyPA, whereas
mutation of the other seven prolines to alanine had no
effect on the binding [26]. Furthermore, mutation of
Gly89 to alanine completely abolished gag binding to
CyPA [26,27], suggesting that binding has an absolute
requirement for glycine preceding proline. Finally, experi-
ments which utilized mutagenesis, centrifugation, and
electron microscopy revealed that CyPA is not required
for HIV-1 virion assembly [27].
In summary, crystallographic and genetic evidence sug-
gests that the binding of the gag protein to CyPA is 
a consequence of the special combination of glycine–
proline. Therefore it is likely that in HIV-1 infectivity
CyPA functions as a chaperone or an essential functional
component, rather than acting as a cis-trans isomerase.
However, the involvement of the cis-trans isomerization
activity of CyPA in HIV-1 infectivity cannot be com-
pletely ruled out, because the crystal structure showed
some similarities between the 25-mer and substrate
AAPF. For example, both the 25-mer and the substrate
AAPF have the same N to C polypeptide chain direction,
the same hydrogen-bonding pattern of the C terminus,
and a similar sidechain conformation of proline. If the
C terminus of the 25-mer  (residues after Pro90) plays a
key role in the HIV-1 infectivity, CyPA might help the
folding of the HIV-1 gag protein by cis-trans isomeriza-
tion. Whether the Gly89–Pro90 bond in the 25-mer
peptide can undergo catalysis of cis-trans isomerization 
by CyPA is under investigation.
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Figure 4
Superposition of the 25-mer fragment (thin
lines) and the peptide AAPF (thick lines). This
figure has an orientation similar to Figure 3,
with the N terminus of the peptides at the
bottom and the C terminus at the top. The
superposition matrix was obtained by
superimposing the CyPA structures. The
C-terminal portion of AAPF (Pro–Phe)
obviously has the same binding conformation
as the 25-mer while the N terminus of AAPF
diverged because Gly89 of the 25-mer
adopted an unusual backbone conformation
(f = 133° and ψ = 160°).
Table 2
The backbone conformations of the 25-mer and AAPF (°).
25mer AAPF
Residue f ψ ω Residue f ψ ω
Val86 –44 173
His87 –95 132 177
Ala88 –72 164 170 Ala1 –82 –38 180
Gly89 133 160 176 Ala2 –88 148 18
Pro90 –65 147 179 Pro3 –81 146 180
Ile91 –78 125 –179 Phe4 –93 129 –176
Ala92 –71 150 165
Pro93 –42 –41 179
Gly94 –71 –28 177
Gln95 –78 –21 180
Nle96 –89 –22 175
Arg97 –144 –54
Biological implications
Cyclophilin A is a peptidyl–prolyl cis-trans isomerase and
also binds the immunosuppressive drug cyclosporin A
(CsA). The peptidyl–prolyl cis-trans isomerization activity
of CyPA has been assumed to play a role in protein fold-
ing [8]. On the other hand, cyclophilins have been reported
to function as chaperones binding several proteins includ-
ing rhodopsin [17] and heat shock proteins [18]. CyPA is
also known to be required for the infectious activity of
human immunodeficiency virus type 1 (HIV-1) [20–22].
However, it is not understood whether the cis-trans iso-
merization activity of CyPA plays a role in the HIV-1
virion activity. The structure of CyPA complexed with a
25 amino acid fragment of the HIV-1 gag capsid protein
may illustrate the role of CyPA in the HIV-1 activity.
The crystal structure of CyPA–25-mer revealed that
Gly89 of the 25-mer has an unfavorable backbone con-
formation (f =133° and ψ =160°); this conformation is
usually only adopted by a glycine residue. The peptide
bond between Gly89 and Pro90 has a trans conforma-
tion, in contrast to the cis conformation observed in
other CyPA–peptide structures [32–37]. These observa-
tions suggest that the binding of CyPA to the gag protein
requires a special sequence combination of glycine–
proline, thus the cis-trans isomerase activity of CyPA is
unlikely to be involved in the HIV-1 infectious activity.
Genetic and biochemical studies showed that CyPA is
required for HIV-1 replication and infectivity, but not
for HIV-1 virion assembly [26,27]. Therefore, CyPA
probably functions as a chaperone or a functional com-
ponent, and not as a cis-trans isomerase, in HIV-1 infec-
tivity. However, the involvement of the cis-trans isomer-
ization activity of CyPA in the function of HIV-1
virions cannot be completely ruled out, because the
25-mer and the isomerase substrate succinyl-Ala-Ala-
Pro-Phe-p-nitroanilide share some similarities in their
C-terminal residues.
Materials and methods
The 25-mer of HIV-1 gag protein was synthesized as described else-
where [44]. It has an amino acid sequence of Ac-Asp-Arg-Val-His-Pro-
Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-Nle-Arg-Glu-Pro-Arg-Gly-Ser-A
sp-Ile-Ala-NH2 corresponding to the sequence numbers 81–105 of the
HIV gag CA except for Nle96 (norleucine) in the 25-mer but Met96 in
the CA sequence [20].
Recombinant human CyPA was purified as previously described [45].
The complex of CyPA–25-mer was prepared by mixing the 25-mer of
HIV-1 gag CA with CyPA in a molecular ratio of 1:1. Cocrystals of the
CyPA–25mer complex were grown at room temperature by the vapor
diffusion method. The well buffer was 90 mM Tris-HCl (pH 8.2), 41 %
saturated ammonium sulfate (AS), and 4.5 mM sodium azide. The
protein drop contained 50 mM Tris-HCl (pH 8.2), 6 % saturated AS,
and 0.32 mM CyPA and the 25-mer. The crystals were formed in 2–4
days and diffracted extremely well. The space group was P212121, with
cell dimensions of a = 44.3, b = 53.1, and g = 68.5 Å. One molecule of
the CyPA–25-mer complex exists in the crystallographic asymmetric
unit, giving a Vm (volume of unit cell/molecular weight) of 1.92 Å3 per
dalton. The solvent content in the crystal is estimated to be in a range
of 20–25 %. Thus, the CyPA–25-mer complex is one of the most
dense protein crystals.
Diffraction data were collected at room temperature on the Rigaku
phosphate image plate system R-AXIS II and processed by the R-AXIS
software. A total of 58 111 measurements were merged and reduced
to 14 651 independent reflections with an Rmerge of 0.0675. This data
set is 94.3 % complete to 1.8 Å resolution (Table 3).
The structure of the CyPA–25-mer complex was determined by the
molecular replacement program AMoRe [46], using unligated CyPA as
the initial model. The cross-rotation function of AMoRe resulted in two
peaks. The translation search on the second peak of the cross-rotation
function yielded a solution with a correlation coefficient of 0.589 and
an R factor of 0.371 for data within the resolution range of 8–4 Å. The
refinement on the rotation and translation by AMoRe yielded a correla-
tion coefficient of 0.839 and an R factor of 0.340 for data between
15–2 Å resolution.
The solution from molecular replacement was first refined as a rigid
body by the program X-PLOR [47] on a Dec Alpha server, yielding an
R factor of 0.376 for the data at 8–1.8 Å resolution. Subsequently, the
structure which included only CyPA was refined by positional and
B factor refinement on individual atoms to an R factor of 0.281 (for data
at 8–1.8 Å resolution). Two electron-density maps with coefficients of
(2Fo–Fc) and (Fo–Fc) were calculated from this model and consistently
revealed the binding and the Ca trace of the 25-mer. The model was
built using the program FRODO/TOM [48] linked to a Silicon graphics
system. After adding 12 amino acids of the 25-mer, further positional
and B factor refinement brought the R factor to 0.243. Solvent mol-
ecules were then automatically picked up and incorporated into the
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Table 3
Data collection and refinement statistics for the structure of
CyPA–25-mer.
Data collection statistics
Space group P212121
Cell a / b / c (Å) 44.3 / 53.1 / 68.5
Total measurements 58 111
Unique reflections 14 651
Rmerge (Å)* 0.0675
Completeness (%)
overall† 94.2
outer shell‡ 88.3
Molecular replacement††
a / b / g (°) 83 / 50 / 243
Tx / Ty / Tz 0.238 / 0.013 / 0.148
Correlation coefficient 0.839
R factor§ 0.34
Refinement statistics
Resolution range (Å) 8.0–1.8
No. of residues CyPA 165 (1266 atoms)
No. of residues 25-mer 12  (86 atoms)
No. of waters 89
R factor 0.195
Rfree# 0.256
Rms
bond (Å) 0.014
angle (°) 2.8
*Rmerge calculated for data at 1.8 Å resolution. †Completeness for data
at 1.8 Å resolution; ‡completeness for the shell 2–18 Å. ††As defined in
AmoRe [46]. §Rfactor for data between 15–2 Å. #Rfree is equivalent to
the R factor for a randomly selected 8 % subset of reflections not used
in structure refinement.
refinement. After each round of refinement, water molecules with a high
B factor were deleted, and new solvent molecules were picked up from
the (Fo–Fc) map and added into the refinement. This water picking refin-
ing procedure was repeated until no peaks stronger than 3.5s were
found in the (Fo–Fc) map. The final structure includes 165 residues of
CyPA, 12 residues of the gag 25-mer, and 89 water molecules; the
structure has an R factor of 0.195 and Rfree of 0.256 for 14 454 reflec-
tions between 8 to 1.8 Å resolution (Table 3). The structure comparison
was performed with the program SUPERIMP or X-PLOR.
Accession numbers
The atomic coordinates have been deposited in the Protein Data Bank with
accession code 1FGL. 
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